Feature | May 22, 2014

Nearly All ICD Implants Performed on Insured Patients

Majority of ICD patients are also male — new study presented at HRS from more than 160,000 ICD implants

ICD Implants Heart Rhythm Society Clinical Study Insurance Male

May 22, 2014 — A study presented at Heart Rhythm 2014, the Heart Rhythm Society’s 35th Annual Scientific Sessions, reports significant gender and health insurance disparities in implantable cardioverter defibrillator (ICD) procedures. For the first time in nearly a decade, the new analysis of ICD implants in the United States shows a majority of implants are performed on people with insurance and more commonly in the male population.

ICDs are small devices, about the size of a small cell phone, that are placed below the collarbone. Via wires or leads, these devices continuously monitor the heart’s rhythm. If the heart beats too quickly or too slowly, the ICD issues a jolt of electricity to restore the heart’s normal rhythm. People with heart muscle damage or “heart failure” have greater chance of having a dangerously fast heart rhythm that ICDs treat. ICDs are very effective in stopping life-threatening arrhythmias and considered one of the most successful therapies to treat arrhythmias.

The authors of the study queried data from the National Inpatient Sample from 2000-2011 using ICD-9 procedure codes for ICD implantation. ICD utilization was assessed in the following four groups: male insured, male uninsured, female insured and female uninsured. More than 160,000 (160,296) estimated ICD implants were identified in people over the age of 18. Almost all (95 percent) of the ICD implants identified were performed in the insured population. The male population with insurance (70.8 percent) had significantly higher implants compared with the female population with insurance (24.2 percent). Only 5 percent of the procedures were performed on people who did not have insurance.

“The striking results show that major disparities are present with ICD implants and this further highlights the importance of adhering to guidelines, so best possible candidates have access to the life saving device,” said lead author Nileshkumar Patel, MBBS, Staten Island University Hospital in New York. “We are presented with the challenge to look for new ways to enhance the quality of care and continue to educate on the safety and effectiveness of these devices.”

Abhishek Deshmukh, co-author of the study, cardiologist at University of Arkansas for Medical Sciences added, “On the surface, efforts are made toward the mitigation of disparities, but closer examination shows that there is still more work to be done especially in current challenging healthcare landscape.”

For more information: www.HRSonline.org

Related Content

St. Jude Medical, ADO II AS trial, congenital heart disease, PDA, Amplatzer Duct Occluder II AS
News | Congenital Heart| October 19, 2016
St. Jude Medical Inc. announced the launch of the ADO II AS (AMPLATZER Duct Occluder II Additional Sizes) pediatric...
Inventory management, Cardinal, RFID inventory tracking, cath lab inventory
Sponsored Content | Whitepapers | Inventory Management| October 18, 2016
As healthcare moves into the era of bundled payments, providers need to be especially focused on ensuring delivery of
Lantheus, flurpiridaz F-18, myocardial perfusion imaging, MPI, cardiac stress testing, ASNC 2016
News | Radiopharmaceuticals and Tracers| October 17, 2016
Lantheus Holdings Inc. announced in late September that sub-analysis data from the first Phase 3 study of flurpiridaz F...
Medtronic, FIRE AND ICE trial, Arctic Front, cryoballoon catheter ablation, radiofrequency RF ablation, study results, Asia Pacific Heart Rhythm Society Scientific Sessions
News | Ablation Systems| October 17, 2016
Medtronic plc last week unveiled new health economic analysis data from the FIRE AND ICE trial that favor cryoballoon...
Medtronic, FDA approval, MRI, MR-conditional scanning, cardiac devices
Technology | EP Lab| October 13, 2016
Medtronic plc is the first company to receive U.S. Food and Drug Administration (FDA) approval for its suite of cardiac...
transcarotid artery revascularization, TCAR Surveillance Project, Society for Vascular Surgery Patient Safety Organization, SVS PSO,
News | Stents Carotid| October 13, 2016
A surveillance project to evaluate the safety and effectiveness of transcarotid artery revascularization (TCAR) in...
Shockwave lithoplasty system, VIVA 16, Vascular Interventioanl Advances, VIA Physicians, late-breaking endovascular clinical trial results
News | Cath Lab| October 12, 2016
VIVA (Vascular Interventional Advances) Physicians announced a number of highly anticipated late-breaking clinical...
News | Renal Denervation| October 11, 2016
Awards from the National Institutes of Health’s Common Fund are supporting research on the peripheral nervous system,...
ZipLine Medical, Zip Surgical Skin Closure, cath lab time savings, PACE study
News | EP Lab| October 10, 2016
October 10, 2016 — ZipLine Medical Inc.
Mercator MedSystems, Bullfrog Micro-Infusion Device, DANCE trial, VIVA 2016, 13-month results
News | Peripheral Arterial Disease (PAD)| October 07, 2016
Mercator MedSystems recently announced that 13-month data from the DANCE trial was presented during a late-breaking...
Overlay Init